litlas
Log inCreate account

Allan Lipton

Active 1970–2023

104
Papers
23,546
Citations
87
h-index
104
i10-index

Citations

Citations per year for Allan Lipton1948: 2 citations1970: 1 citations1971: 6 citations1972: 8 citations1973: 10 citations1974: 9 citations1975: 8 citations1976: 8 citations1977: 14 citations1978: 19 citations1979: 14 citations1980: 16 citations1981: 21 citations1982: 25 citations1983: 22 citations1984: 15 citations1985: 8 citations1986: 13 citations1987: 8 citations1988: 16 citations1989: 22 citations1990: 15 citations1991: 8 citations1992: 18 citations1993: 26 citations1994: 28 citations1995: 20 citations1996: 32 citations1997: 44 citations1998: 60 citations1999: 70 citations2000: 96 citations2001: 155 citations2002: 145 citations2003: 209 citations2004: 179 citations2005: 187 citations2006: 181 citations2007: 205 citations2008: 219 citations2009: 263 citations2010: 230 citations2011: 285 citations2012: 210 citations2013: 182 citations2014: 150 citations2015: 163 citations2016: 110 citations2017: 112 citations2018: 98 citations2019: 297 citations2020: 357 citations2021: 269 citations2022: 170 citations2023: 108 citations2024: 152 citations2025: 58 citations2026: 5 citations1949–1969: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,627 citing papers, 32% of this breakdownUnited Kingdom: 418 citing papers, 8.2% of this breakdownItaly: 284 citing papers, 5.6% of this breakdownChina: 257 citing papers, 5.1% of this breakdownGermany: 232 citing papers, 4.6% of this breakdownCanada: 222 citing papers, 4.4% of this breakdownFrance: 204 citing papers, 4% of this breakdownJapan: 165 citing papers, 3.2% of this breakdownSwitzerland: 164 citing papers, 3.2% of this breakdownAustralia: 150 citing papers, 3% of this breakdownSpain: 110 citing papers, 2.2% of this breakdownBelgium: 108 citing papers, 2.1% of this breakdown
0%32%Other 22.4%

Institutions

Fields

  • Medicine73.8%
  • Biochemistry, Genetics and Molecular Biology20.8%
  • Immunology and Microbiology1.5%
  • Engineering0.7%
  • Neuroscience0.5%
  • Economics, Econometrics and Finance0.5%
  • Other2.2%

Topics

  • Bone health and treatments13.7%
  • Management of metastatic bone disease3.8%
  • Bone Metabolism and Diseases3.4%
  • Bone health and osteoporosis research3.2%
  • Estrogen and related hormone effects2.9%
  • Radiopharmaceutical Chemistry and Applications2.8%
  • Other70.2%

Coauthors

All papers

Open in search
  1. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

    Authors: Alison Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G. Steger, Katia Tonkin, Richard H. De Boer, Mikhail Lichinitser, Yasuhiro Fujiwara, Denise A. Yardley, María Eugenia Ibarrarán Viniegra, Michelle Fan, Qi Jiang, Roger Dansey, Susie Jun, Ada Braun - Journal of Clinical Oncology 2010 cited by 1,593

  2. Pathologic fractures correlate with reduced survival in patients with malignant bone disease

    Authors: Fred Saad, Allan Lipton, Richard J. Cook, Yin‐Miao Chen, Matthew R. Smith, Robert E. Coleman - Cancer 2007 cited by 661

  3. Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval

    Authors: Benoît Cadieux, Robert E. Coleman, Pegah Jafarinasabian, Allan Lipton, Robert Z. Orlowski, Fred Saad, Giorgio V. Scagliotti, Kazuyuki Shimizu, Alison Stopeck - Journal of bone oncology 2022 cited by 62

  4. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

    Authors: Allan Lipton, Karim Fizazi, Alison Stopeck, David H. Henry, Janet E. Brown, Denise A. Yardley, Gary Richardson, Salvatore Siena, Pablo Maroto, Michael Clemens, Boris Bilynskyy, Veena Charu, Philippe Beuzeboc, Michael Rader, María Eugenia Ibarrarán Viniegra, Fred Saad, Chunlei Ke, Ada Braun, Susie Jun - European Journal of Cancer 2012 cited by 589

  5. Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

    Authors: Ritwik Ghosh, Archana Narasanna, Shizhen Emily Wang, Shuying Liu, Anindita Chakrabarty, Justin M. Balko, Ana M. González-Angulo, Gordon B. Mills, Elicia Penuel, John Winslow, Jeff Sperinde, Rajiv Dua, Sailaja Pidaparthi, Ali Mukherjee, Kim Leitzel, Wolfgang J. Köstler, Allan Lipton, Michael Bates, Carlos L. Arteaga - Cancer Research 2011 cited by 224

  6. Synergistic Inhibition with a Dual Epidermal Growth Factor Receptor/HER-2/neu Tyrosine Kinase Inhibitor and a Disintegrin and Metalloprotease Inhibitor

    Authors: Lois Witters, Peggy Scherle, Steven Friedman, Jordan S. Fridman, Eian Caulder, Robert Newton, Allan Lipton - Cancer Research 2008 cited by 116

  7. Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients

    Authors: Jeff Sperinde, Xueguang Jin, Jayee Banerjee, Elicia Penuel, Anasuya Saha, Gundo Diedrich, Weidong Huang, Kim Leitzel, Jodi Weidler, Suhail M. Ali, Eva‐Maria Fuchs, Christian F. Singer, Wolfgang J. Köstler, Michael Bates, Gordon Parry, John Winslow, Allan Lipton - Clinical Cancer Research 2010 cited by 169

  8. Hypocalcaemia in patients with metastatic bone disease treated with denosumab

    Authors: Jean-Jacques Body, Henry G. Bone, Richard H. De Boer, Alison Stopeck, Catherine Van Poznak, Ronaldo Damião, Karim Fizazi, David H. Henry, Toni Ibrahim, Allan Lipton, Fred Saad, Neal D. Shore, Toshimi Takano, Adam J. Shaywitz, Huei Wang, Oswaldo L. Bracco, Ada Braun, Paul J. Kostenuik - European Journal of Cancer 2015 cited by 150

  9. The Science and Practice of Bone Health in Oncology: Managing Bone Loss and Metastasis in Patients With Solid Tumors

    Authors: Allan Lipton, Robert G. Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman, Matthew R. Smith - Journal of the National Comprehensive Cancer Network 2009 cited by 118

  10. Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer

    Authors: Nicholas Willumsen, Suhail M. Ali, Kim Leitzel, Joseph J. Drabick, Nelson S. Yee, Hyma Polimera, Vinod Nagabhairu, Laura Krecko, Sajid Ali, Ashok Maddukuri, Prashanth Moku, Aamnah Ali, Joyson Poulose, Harry Menon, Neha Pancholy, Luís Costa, M.A. Karsdal, Allan Lipton - Scientific Reports 2019 cited by 58

  11. Oncobiology and treatment of breast cancer in young women

    Authors: Rakesh Kumar, Catarina Abreu, Masakazu Toi, Sunil Saini, Sandra Casimiro, Anshika Arora, Aswathy Mary Paul, Ravi Velaga, Pranela Rameshwar, Allan Lipton, Sudeep Gupta, Luís Costa - Cancer and Metastasis Reviews 2022 cited by 46

  12. Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types

    Authors: Nicholas Willumsen, Christina Jensen, George Green, Neel I. Nissen, Jaclyn Neely, David M. Nelson, Rasmus S. Pedersen, Peder Frederiksen, Inna M. Chen, Mogens K. Boisen, Astrid Z. Johansen, Daniel H. Madsen, Inge Marie Svane, Allan Lipton, Kim Leitzel, Suhail M. Ali, Janine T. Erler, Daan P. Hurkmans, Ron H.J. Mathijssen, Joachim G.J.V. Aerts, Mohammed Eslam, Jacob George, Claus Christiansen, Mina J. Bissel, M.A. Karsdal - Cellular and Molecular Life Sciences 2022 cited by 35

  13. Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors

    Authors: J. E. Brown, Richard J. Cook, Pierre Major, Allan Lipton, F. Saad, Matthew Smith, Ker‐Ai Lee, Ming Zheng, Y. Hei, Robert E. Coleman - JNCI Journal of the National Cancer Institute 2005 cited by 564

  14. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone

    Authors: Gabriel N. Hortobágyi, Catherine Van Poznak, W G Harker, William J. Gradishar, Helen K. Chew, Shaker R. Dakhil, Barbara Haley, Nicholas Sauter, Ramon Mohanlal, Ming Zheng, Allan Lipton - JAMA Oncology 2017 cited by 159

  15. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease

    Authors: Evangelos Terpos, James R. Berenson, Richard J. Cook, Allan Lipton, Robert E. Coleman - Leukemia 2010 cited by 121

  16. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

    Authors: Allan Lipton, Karim Fizazi, Alison Stopeck, David H. Henry, Mitchell R. Smith, Neal D. Shore, Miguel Martín, Saroj Vadhan‐Raj, Janet E. Brown, Gary Richardson, Fred Saad, Denise A. Yardley, Kefei Zhou, Arun Balakumaran, Ada Braun - European Journal of Cancer 2015 cited by 114

  17. Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

    Authors: Karim Fizazi, Allan Lipton, Xavier Mariette, Jean‐Jacques Body, Yasmin Rahim, Julie R. Gralow, Guozhi Gao, Ling Wu, Winnie Sohn, Susie Jun - Journal of Clinical Oncology 2009 cited by 534

  18. Pain outcomes in patients with advanced breast cancer and bone metastases

    Authors: Charles S. Cleeland, Jean‐Jacques Body, Alison Stopeck, Roger von Moos, Lesley Fallowfield, Susan D. Mathias, Donald L. Patrick, Mark Clemons, Katia Tonkin, Norikazu Masuda, Allan Lipton, Richard de Boer, Stefania Salvagni, Célia Tosello Oliveira, Yi Qian, Qi Jiang, Roger Dansey, Ada Braun, Karen Chung - Cancer 2012 cited by 155

  19. SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer

    Authors: Fred Saad, Allan Lipton - Cancer Treatment Reviews 2009 cited by 124

  20. Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?

    Authors: Peyman Hadji, Michael Gnant, J.J. Body, Nigel Bundred, Adam Brufsky, Rob Coleman, Theresa A. Guise, Allan Lipton, Matti Aapro - Cancer Treatment Reviews 2012 cited by 101

  21. Implications of Bone Metastases and the Benefits of Bone-Targeted Therapy

    Authors: Allan Lipton - Seminars in Oncology 2010 cited by 80

  22. Diagnostic delays in breast cancer among young women: An emphasis on healthcare providers

    Authors: Luís Costa, Rakesh Kumar, Cynthia Villarreal‐Garza, Saket Sinha, Sunil Saini, Jayanti Semwal, Vartika Saxsena, Vaishali Zamre, Chintamani Chintamani, Mukurdipi Ray, Chikako Shimizu, Lejla Hadzikadic Gusic, Masakazu Toi, Allan Lipton - The Breast 2023 cited by 43

  23. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer

    Authors: Bruce E. Hillner, James N. Ingle, Rowan T. Chlebowski, Julie R. Gralow, Gary C. Yee, Nora A. Janjan, Jane A. Cauley, Brent A. Blumenstein, Kathy S. Albain, Allan Lipton, Susan Brown - Journal of Clinical Oncology 2003 cited by 973

  24. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

    Authors: James R. Berenson, Alan Lichtenstein, Lisa A. Porter, Meletios Α. Dimopoulos, Rodolfo Bordoni, Saby George, Allan Lipton, Alan Keller, Oscar Ballester, Michael J. Kovacs, Hillary Blacklock, R. Bell, Joseph F. Simeone, Dirk J. Reitsma, M Heffernan, John J. Seaman, Robert Knight - Journal of Clinical Oncology 1998 cited by 653